4//SEC Filing
Ullem Scott B. 4
Accession 0001225208-25-009067
CIK 0001099800other
Filed
Nov 9, 7:00 PM ET
Accepted
Nov 10, 6:07 PM ET
Size
11.5 KB
Accession
0001225208-25-009067
Insider Transaction Report
Form 4
Ullem Scott B.
CVP, CFO
Transactions
- Sale
Common Stock
2025-11-10$83.30/sh−2,974$247,734→ 49,924 total - Exercise/Conversion
Common Stock
2025-11-10$59.26/sh+13,000$770,337→ 52,898 total - Sale
Common Stock
2025-11-10$83.02/sh−10,026$832,360→ 39,898 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2025-11-10−13,000→ 46,700 totalExercise: $59.26From: 2020-05-08Exp: 2026-05-07→ Common Stock (13,000 underlying)
Holdings
- 266,318(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $83.270 to $83.415. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $82.270 to $83.260. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Documents
Issuer
Edwards Lifesciences Corp
CIK 0001099800
Entity typeother
Related Parties
1- filerCIK 0001446989
Filing Metadata
- Form type
- 4
- Filed
- Nov 9, 7:00 PM ET
- Accepted
- Nov 10, 6:07 PM ET
- Size
- 11.5 KB